AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Defence Therapeutics Receives USPTO Allowance for ADC Patent Application
ByAinvest
Monday, Jun 9, 2025 3:16 am ET1min read
Defence Therapeutics has received a Notice of Allowance from the USPTO for its patent application covering next-generation ADC technology. The patent will provide the company with potential market exclusivity until 2043 for its proprietary second-generation Accum-based ADCs. This milestone builds on Defence's established patent portfolio for its foundational Accum technology. The company's ADC platform technology represents a significant advancement in oncotherapy and targeted drug delivery.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) has received a Notice of Allowance from the USPTO for its patent application covering next-generation ADC technology. This significant milestone grants the company potential market exclusivity until 2043 for its proprietary second-generation Accum-based ADCs [2].The patent builds upon Defence's established patent portfolio for its foundational Accum technology. The company's ADC platform technology represents a significant advancement in oncotherapy and targeted drug delivery. Defence Therapeutics is a leading biotechnology company specializing in advanced endosomal escape technologies, with a focus on developing next-generation radio-immuno-conjugate and ADC products using its proprietary Accum® technology [2].
The new patent strengthens Defence Therapeutics' position in the competitive biotechnology landscape and positions the company at the forefront of innovation in the ADC market. The company's expansion into the Boston-Cambridge area further underscores its commitment to advancing cutting-edge research and development in one of the world's foremost biotech clusters [2].
This development is a testament to Defence Therapeutics' commitment to pushing the boundaries of targeted cancer therapies. The company's Accum® technology enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, increasing efficacy and potency against cancer [2].
With this patent, Defence Therapeutics is well-positioned to continue its mission of advancing the Accum® platform for next-generation ADCs. The company's strategic expansion and technological advancements highlight its potential to make a significant impact on the oncology market.
References:
[1] https://finance.yahoo.com/news/obi-pharma-enters-adc-collaboration-070000695.html
[2] https://www.biospace.com/press-releases/defence-therapeutics-opens-u-s-laboratory-in-boston-cambridge-biotech-hub
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet